Lebrikizumab
EBGLYSS
Pronunciation: leb-ri-KIZ-yoo-mab (EB-glis)
“The breeze kiss you (maybe) → Egg bliss”
What it isMonoclonal antibody selectively neutralizing IL-13; moderate-to-severe atopic dermatitis.
Why this oneUnlike tralokinumab, it preserves IL-13 binding to its decoy receptor while blocking pathogenic signaling.
What limits itConjunctivitis and keratitis can end treatment; address helminth infection first and avoid live vaccines.
FDA-approved for
- Moderate-to-severe atopic dermatitis (2024)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Moderate-to-severe atopic dermatitis (inadequately controlled with topical Rx or when not advisable) | Adults and pediatric 12 yr and older weighing >=40 kg | 500 mg (two 250 mg injections) SC at Week 0 and Week 2 | 250 mg SC every 2 weeks until Week 16 or later, then 250 mg every 4 or every 8 weeks (maintenance) |
Renal No clinically significant differences in mild or moderate renal impairment (no dedicated study)
Hepatic Undefined (not studied; not expected to undergo significant hepatic elimination)
Instructions
- Administer by subcutaneous injection (abdomen, thigh, or back of upper arm)
- Complete all age-appropriate vaccinations before starting; avoid live vaccines during treatment
- May be used with or without topical corticosteroids
Available strengths
- inj 250 mg/2 mL
Contraindications
- Prior serious hypersensitivity to lebrikizumab-lbkz or any excipients in EBGLYSS
Cautions
- Hypersensitivity reactions including angioedema and urticaria
- Conjunctivitis and keratitis
- Parasitic (helminth) infections - treat pre-existing infection before starting
- Avoid live vaccines during treatment
Adverse reactions
- Conjunctivitis
- Injection site reactions
- Herpes zoster
Pregnancy Insufficient human data; monoclonal antibodies are actively transported across the placenta. No adverse embryo-fetal effects in monkeys.
Lactation No data on presence in human milk; endogenous IgG and monoclonal antibodies are present in human milk.
Cost
| Strength | #/mo | generic $/unit | brand $/unit | CostPlus | |
|---|---|---|---|---|---|
| 250 mg/2 mL | inj | per unit | — | $1783.52/mL | not offered |
NO BOXED WARNINGS
Principal riskConjunctivitis
Classes and tags
Clinical profile
Legacy pregnancy categoryN/A (post-2015 labeling)
Defining liabilityConjunctivitis, keratitis and hypersensitivity reactions